Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept plus rituximab versus placebo plus rituximab in active rheumatoid arthritis
2007-003647-75Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Nov 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Atacicept + rituximab with Placebo + rituximab (2 arms). Primary endpoint: Safety and tolerability. Started Nov 2007; status: completed.
02
Drugs
ataciceptrituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-003647-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003647-75.